NIKKEI 225
27,772.93 +305.70 (+1.11%) HANG SENG
24,819.07 +691.22 (+2.86%) CRUDE OIL
87.27 +0.31 (+0.36%) GOLD FUTURES
1,839.40 -3.80 (-0.21%) DOW
35,028.65 -339.82 (-0.96%) BTC-GBP
30,840.28 +45.66 (+0.15%)
Grifols, S.A. (GRF.MC)
| Previous close | 16.92 |
| Open | 16.87 |
| Bid | 16.84 x 0 |
| Ask | 16.86 x 0 |
| Day's range | 16.74 - 17.19 |
| 52-week range | 15.08 - 26.07 |
| Volume | |
| Avg. volume | 1,106,665 |
| Market cap | 9.85B |
| Beta (5Y monthly) | 0.18 |
| PE ratio (TTM) | 17.35 |
| EPS (TTM) | 0.97 |
| Earnings date | 24 Feb 2022 - 28 Feb 2022 |
| Forward dividend & yield | 0.36 (2.22%) |
| Ex-dividend date | 03 Jun 2021 |
| 1y target est | 25.40 |
- Reuters
Spain's Grifols to buy rival Biotest for up to $1.9 billion
MADRID (Reuters) -Spanish pharmaceuticals company Grifols proposed a 1.6 billion euro ($1.9 billion) takeover of its German rival Biotest on Friday, in a move to consolidate the plasma-based drug industry. Grifols said it had agreed with Tiancheng International Investment to buy the Hong Kong-based company's controlling stake in Biotest for 1.1 billion euros. The Barcelona-based company agreed to buy 89.88% of Biotest's ordinary shares that carry voting rights, but which represent only 44.54% of the company's capital, and a further 0.54% of capital in preferred shares that do not carry voting rights, from Hong Kong-based Tiancheng.
- Zacks
Moving Average Crossover Alert: Grifols (GRFS)
Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
- Zacks
New Strong Sell Stocks for March 8th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
